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This report describes atypical absence seizures induced by phenobarbital (PB) in a patient with benign childhood epilepsy
with centrotemporal spikes. An 11-year-old girl had nocturnal motor seizures, beginning at the age of 7 years. Interictal EEG
displayed centrotemporal sharp waves in the left and right sides alternatively, which increased significantly in frequency during
sleep. She was given a diagnosis of benign childhood epilepsy with centrotemporal spike and was treated with valproic acid
(VPA), which controlled her seizures for 3 years. She experienced nocturnal Rolandic seizures again, at the age of 10 years
2 months, 10 years 10 months in spite of the regular medication, and PB 60 mg daily was added to the VPA. Her parents noted
de novo a few seconds of unresponsive fits 7 days after PB administration. Ictal EEG of the fits revealed diffuse irregular spike
and wave bursts (1–4 seconds). VPA and PB in her blood was within the therapeutic ranges. After discontinuing PB, the atypical
absence seizures immediately disappeared. Phenobarbital should be added to the list of drugs that potentially provoke de novo
seizures.
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INTRODUCTION
It is well known that some anticonvulsants may
precipitate or exacerbate seizures although the serum
concentration will be within the therapeutic range.
Most of the reported cases with such adverse reaction
were treated with carbamazepine or phenytoin. Pheno-
barbital (PB) is used widely in the world and has been
used for a long time. Some cases have been reported to
have involuntary movement induced by PB. Atypical
absence seizures induced by PB have not been
reported, according to our limited knowledge. This
report describes atypical absence seizures provoked by
PB in a patient with benign childhood epilepsy with
centrotemporal spike (BECTS).
PATIENT REPORT
An 11-year-old girl had nocturnal motor seizures,
including hemifacial spasms with drooling or hemi-
convulsion, beginning at the age of 7 years. Her past
medical history and family history were uneventful,
and her developmental milestones were normal. Neu-
rological examination and brain magnetic resonance
imaging revealed no abnormality. Interictal EEG
displayed centrotemporal sharp waves in the left and
right sides alternatively, which increased significantly
in frequency during sleep. She was given a diagnosis
of BECTS and treated with valproic acid (VPA)
600 mg daily, which controlled her seizures well for
3 years. She experienced Rolandic seizures again, at
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Fig. 1: Electroencephalograms at the age of 11 years, including ictal record (awake). The dots indicate that centrotemporal sharp
waves appeared in the left and right sides alternatively. The arrow shows the beginning of atypical absence seizures, which
continued for a few seconds only accompanied with diffuse irregular sharp and wave bursts. As soon as the sharp and wave
bursts ended, the patient could respond quickly to her name.
the age of 10 years 2 months, 10 years 10 months in
spite of the regular medication, and PB 60 mg daily
was added to the VPA. Her parents noted de novo
a few seconds of unresponsive fits 7 days after PB
was begun. These fits increased every few minutes
in frequency while she was awake, and developed
to being accompanied with head nodding or eye
blinking one month later. Ictal EEG of the fits revealed
diffuse irregular spike and wave bursts (1–4 seconds).
Electromyogram of the bilateral trapezius showed no
significant change (Figs 1 and 2). The alteration of
muscle tone of the neck, trunk and extremities was
obscure during the fits, for a short duration of the fits,
except for the disappearance of artefacts of muscle
activities which were superimposed bilaterally on Fp1
of figure. As soon as the spike and wave bursts ended,
she could respond quickly to her name. We asked her
to try to keep tapping a can with a pen regularly every
second for 5 minutes. The rhythm of the tapping was
delayed during the fits. The serum concentrations of
VPA and PB was 56.0 and 15.6 µg ml−1, respectively;
both of them were within the therapeutic ranges. After
the PB was discontinued, the atypical absence seizures
immediately disappeared. VPA was increased up to
800 mg daily and then she experienced no seizure for
the following 10 months.
DISCUSSION
The rapid appearance of the atypical absences after
adding PB, and also their rapid disappearance after
discontinuing PB indicate that they were induced by
PB; however, a repeat challenge with PB has not
been performed. Carbamazepine and phenytoin have
been the antiepileptic agents which most commonly
induced or aggravated seizures, within or beyond the
therapeutic ranges1–4. There have been several reports
of PB-induced dyskinesia and interictal epileptic
discharges5. No report was found that suggested that
the seizures were induced or aggravated by using
PB, except as an indirect side effect of sleepiness.
This is the first report of PB-induced atypical absence
seizures in BECTS within the therapeutic range.
Seizures induced or aggravated by antiepileptic
drugs should receive more attention. When a patient
of BECTS suffers de novo absence seizures, atypical
benign partial epilepsy might be diagnosed6. How-
Absence induced by phenobarbital 203
Fig. 2: Ictal electroencephalograms of another situation. The arrow shows the beginning of atypical absence seizures.
Paroxysmal discharges in the right centro-midtemporal region preceded diffuse spike and wave. This electroencephalogram
reveals marked irregularity of diffuse spike and wave and predominance in the right centro-midtemporal region.
ever, those seizures may include seizures induced
or aggravated by antiepileptic drugs, even by PB.
Misdiagnosis may lead to polypharmacy, instead of
discontinuing the drug which probably induced the
seizures.
The mechanism by which PB produced atypical
absence seizures in this patients is not clear. Benzo-
diazepines (BZDs) have been reported to exacerbate
tonic status epilepticus in patients with Lennox–
Gastaut syndrome and to induce microseizures in
those with West syndrome7–9. Both BZDs and PB
enhance postsynaptic γ -aminobutyric acid (GABA)
receptor current by which rapid inhibition is mediated
in the central nervous system, to provoke anticonvul-
sive effects10, 11. The duration of PB administration
was only a short period in this patient; however, exac-
erbation of seizures by BZDs was reported in patients
with chronic treatment of BZDs8–10. VPA, a concomi-
tant medication in this patient, is thought to have two
kinds of antiepileptic properties to intensify the release
of GABA and to reduce sustained, high-frequency,
repetitive firing of action potentials10, 11. The com-
bination of PB and VPA may modulate their effects
on each other to induce atypical absence seizures in
the patient. Whatever the mechanism is, this report
indicates that the combination of PB and VPA in
patient with BECTS may provoke de novo seizures.
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